zinc finger and SCAN domain containing 5CGenealiases: ZNF495C · ZSCAN5CP
Q-omics provides the consensus-scored ZSCAN5C profile across patient tissues and cancer cell-line models. ZSCAN5C expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in MESO. Among the 18 cancer types available for tumor–normal comparison, ZSCAN5C is differentially expressed in 8, with the highest sampling consensus in LIHC. Additionally, ZSCAN5C RNA expression shows 6,611 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight MESO, LIHC, and STAD as cancer lineages where ZSCAN5C shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ZSCAN5C — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ZSCAN5C survival associations across molecular data types. ZSCAN5C RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ZSCAN5C RNA expression–survival associations across cancer types. High ZSCAN5C expression shows unfavorable associations in MESO, UCEC, DLBC, KICH, LIHC and KIRP. The MESO Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify MESO as the clearest survival context for ZSCAN5C RNA expression.
This table summarizes ZSCAN5C tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in LIHC for RNA.
This table ranks reproducible tumor–normal expression differences for ZSCAN5C. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ZSCAN5C shows lower tumor expression in KICH and higher tumor expression in LIHC, LUSC, BRCA, HNSC and KIRC. The LIHC box plot shows higher ZSCAN5C RNA expression in tumor versus normal tissue (log2 FC = +0.045, t-test p < 0.001).
This table shows molecular features associated with ZSCAN5C in patient tissues and cancer cell lines. In patient samples, ZSCAN5C shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set. In cancer cell lines, ZSCAN5C RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in LUNG_NSCLC_LUAD and LARGE_INTESTINE.
